TH
Therapeutic Areas
Akros Pharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| JTE-051 | Autoimmune diseases, Allergic diseases | Phase2 |
| JTT-662 | Type 2 diabetes mellitus | Phase1 |
| JTT-861 | Chronic heart failure | Phase2 |
| JTC-064 | Neurodegenerative disease | Phase1 |
| JTV-161 | Pulmonary arterial hypertension | Phase1 |
| JTE-162 | Autoinflammatory/Autoimmune diseases | Phase1 |
| JTC-262 | Neurodegenerative disease | Phase1 |
| JTV-263 | Peripheral artery disease | Phase1 |
Leadership Team at Akros Pharma
TN
Takanori Nemoto, M.S.
Vice President, Clinical Development
TJ
Timothy J. Babcock, Esq.
Vice President, Intellectual Property
SP
Sudhakar Pai, Ph.D., FCP
Senior Director, Clinical Pharmacology
KP
Kala Patel, R.Ph.,RAC.
Senior Director, Regulatory Affairs